Metalloproteinases and their tissue inhibitors in multiple sclerosis

Journal of Autoimmunity

Volumn 12, Issue 4, 1999, Pages 297-303

  Özenci, Volkan ^a   Rinaldi, Luciano ^a   Teleshova, Natalia ^a   Matusevicius, Darius ^a   Kivisäkk, Pia ^a   Kouwenhoven, Mathilde ^a   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebrospinal fluid; In situ hybridization; Metalloproteinases; Multiple sclerosis; Tissue inhibitors of metalloproteinases

Indexed keywords

MESSENGER RNA; METALLOPROTEINASE; MYELIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0033019814     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1999.0285     Document Type: Article

References (31)

1. Calder V., Owen S., Watson C., Feldman M., Davidson A. MS: a localized immune disease of the central nervous system. Immunol. Today. 10:1989;99-103.
2. Kermode A.G., Thompson A.J., Tofts P., MacManus D.G., Kendall B.E., Kingsley D.P., Mooseley I.F., Rudge P., McDonald W.I. Breakdown of the blood brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain. 113:1990;1477-1489.
3. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., Piott R., Stabler G., Ward G.A., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-alpha inhibitor. J. Neuroimmunol. 74:1997;85-94.
4. Matrisian L.M. The matrix degrading metalloproteinases. Bioassays. 14:1992;455-463.
5. Chandler S., Miller K.M., Lury J., Corkill D., Anthony D.C., Adams S.E., Gearing A.J. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72:1997;155-161.
6. Gearing A.J.H., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L., Leber T.M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L.M., Wooley K. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature. 370:1994;555-557.
7. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201:1995;223-226.
8. Proost P., Van Damme J., Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192:1993;1175-1181.
9. Gijbels K., Galardy R.E., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroximate inhibitor of metalloproteinases. J. Clin. Invest. 94:1994;2177-2182.
10. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis Rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44:1995;345-349.
11. Steinman L., Gijbels K. Gelatinase B producing cells in multiple sclerosis lesions. J. Cell. Biochem. 18(Suppl. D):1994;143.
12. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 42:1992;29-34.
13. Rosenberg G.A., Dencoff J.E., Correa N., Reiners M., Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 46:1996;1626-1632.
14. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogeneous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
15. Docherty A.J., O'Connel J., Crabbe T., Angal S., Murphy G. The matrix metalloproteinases and their neutral inhibitors: prospects for treating degenerative tissue diseases. TIBTECH. 10:1992;200-207.
16. Stetler-Stevenson W.G., Brown P.D., Onisto M., Levy A.T., Liotta L.A. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J. Biol. Chem. 165:1990;13933-13938.
17. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:1995;4379-4389.
18. DeClerck Y.A., Yean T.-D., Ratzkin B.J., Lu H.S., Langley K.E. Purification and characterization of two related but distinct metalloprotease inhibitors secreted by bovine aortic endothelial cells. J. Biol. Chem. 264:1989;17445-17450.
19. Goldberg G.I., Marmer B.L., Grant G.A., Eisen A.Z., Wilhelm S., He C. Human 72-kilodalton type IV collagenase forms a tissue inhibitor of metalloprotease designated TIMP-2. Proc. Natl. Acad. Sci. USA. 86:1989;8207-8211.
20. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
21. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., Campell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152:1998;729-741.
22. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocoles. Ann. Neurol. 13:1983;227-231.
23. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
24. Link J., Söderström M., Ljungdahl Â., Höjeberg B., Olsson T., Xu Z., Fredrikson S., Wang Z-Y., Link H. Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology. 44:1994;728-734.
25. Saus J., Quinones S., Otani Y., Nagase H., Harris E.D., Kurkinen M. The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J. Biol. Chem. 263:1988;6742-6745.
26. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., Goldberg G.I. SV 40-transformed human lung fibroblasts secrete a 92kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264:1989;17213-17221.
27. Opbroek A., Kenney M.C., Brown D. Characterization of a human corneal metalloproteinase inhibitor (TIMP-1). Curr. Eye Res. 12:1993;877-883.
28. Liotta I.A., Stetler-Stevenson W., Steeg P.S. Metastasis suppressor genes. Imp. Adv. Oncol. 1:1991;85-100.
29. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.
30. Shapiro S.D., Fliszar C.J., Broekelman T.J., Mecham R.P., Senior R.M., Welgus H.G. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J. Biol. Chem. 17:1995;6351-6356.
31. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.